| Proposed Ticker: SNDX | 1945 Palomar Oaks Way | |
| Exchange: NASDAQ-National Market | Carlsbad, California 92009 | |
| Industry: Manufacturing | (619) 930-6300 |
| All share information is proposed | ||||
| Type of Shares: | Common Shares | Filing Date: | 5/10/96 | |
| U.S. Shares Filed: | 2,400,000 | Filing Range: | $11.50 - $13.50 | |
| Non-U.S. Shares Filed: | 0 | Offering Amount: | $30,000,000 | |
| Primary Shares: | 2,400,000 | Expenses: | - | |
| Secondary Shares: | 0 | Shs Out After: | 8,638,978 | |
| Manager | Tier | Phone |
| CS First Boston | Lead Manager | (212) 909-3312 |
| J.P. Morgan Securities Inc. | Co-manager | (212) 648-9922 |
| Needham & Company | Co-manager | (212) 371-8300 |
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 3/31/96 | 3/31/95 | 3/31/96 | ||
| Revenue: | $1.25 | $0.83 | $0.38 | Assets: | $13.95 |
| Net Income: | -$7.81 | -$1.61 | -$1.93 | Liabilities: | $9.69 |
| EPS: | -$1.59 | -$0.32 | Equity: | $4.26 | |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company develops, manufactures and markets blood analysis systems that provide cost-effective measurement of critical diagnostic parameters at the point-of-care ("POC"). POC devices are used by attending clinicians in the patient setting to obtain rapid test results. The Company's SenDx 100 is a portable system which utilizes a single multi-use disposable sensor cassette to accurately and simultaneously measure any combination of seven blood tests frequently ordered for critical care patients in a simple, less than 90 second procedure. The Company received U.S. Food and Drug Administration ("FDA") clearance for the SenDx 100 in December 1995, 68 days from the date of submission of its 510(k) premarket notification. The notification was supported by test data obtained at five hospitals, including nationally recognized teaching hospitals, which compared the SenDx 100 to commonly used central laboratory instruments. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used to increase sales and marketing activities, repay debt, and for research and development, for working capital and for general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.